RECRUITING Phase 2 ClinicalTrials.gov

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

Sponsor: Merck Sharp & Dohme LLC • ClinicalTrials.gov ID: NCT07252739

Registry updated: 2026-09-02

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

Researchers want to learn if using a study medicine called MK-1084 can help treat Non-Small Cell Lung Cancer (NSCLC). MK-1084 is a type of treatment called targeted therapy for the Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C gene change. The goal of this study is to learn about the safety of MK-1084 and to learn how many people have the cancer get smaller or go away during the study treatment.

Interventions

MK-1084 (Drug)
Oral Administration
Pembrolizumab (Biological)
Intravenous administration
Cetuximab (Biological)
Intravenous administration
Sacituzumab tirumotecan (sac-TMT) (Biological)
Injection powder for intravenous infusion
Rescue medication (Drug)
Participants receive the following rescue medications, per approved product label, as premedication to study treatment to prevent hypersensitivity and/or infusion reactions: diphenhydramine (or equivalent histamine-1 \[Hl\] receptor antagonist), H2 receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion, and granulocyte colony-stimulating factor (G-CSF). A steroid mouthwash (dexamethasone or equivalent) will be given as prophylaxis for stomatitis/oral mucositis.

Eligibility criteria

Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Has histologically or cytologically confirmed diagnosis of advanced or metastatic nonsquamous Non-Small Cell Lung Cancer (NSCLC) * Has tumor tissue or circulating tumor deoxyribonucleic acid (ctDNA) that demonstrates the presence of Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C mutations * Can provide an archival tumor tissue sample or newly obtained core, incisional, excisional biopsy of a tumor lesion not previously irradiated * Has recovered to ≤Grade 1 or baseline from any Adverse events (AEs) due to previous anticancer therapies and/or ≤Grade 2 neuropathy and/or endocrine-related AEs adequately treated with hormone replacement * Has well controlled human immunodeficiency virus (HIV) on antiretroviral therapy (ART) if HIV-infected * Has undetectable hepatitis B (HBV) viral load and have received HBV antiviral therapy for at least 4 weeks if hepatitis B surface antigen (HBsAg) positive * Has undetectable hepatitis C (HCV) viral load if HCV-infected Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Has a diagnosis of small cell lung cancer or, for mixed tumors, presence of small cell elements * Has HIV-infection with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease * Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing * Has active inflammatory bowel disease requiring immunosuppressive medication or previous clear history of inflammatory bowel disease * Has uncontrolled, clinically significant cardiovascular disease or cerebrovascular disease, including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, prolongation of corrected QT interval corrected for heart rate by Fridericia's formula (QTcF) interval to \>470 ms, and/or other serious cardiovascular and cerebrovascular diseases within the 6 months preceding study intervention * Has received prior systemic anticancer therapy for advanced or metastatic NSCLC * Has received any prior immunotherapy and was discontinued from that treatment due to a Grade 3 or higher immune-related adverse event (irAE) (except endocrine disorders that can be treated with replacement therapy) or was discontinued from that treatment due to Grade 2 myocarditis or recurrent Grade 2 pneumonitis * Has received previous treatment with an agent targeting KRAS * Has received prior systemic anticancer therapy within 4 weeks or 5 half-lives (whichever is shorter) and has not recovered to grade ≤ 1 or baseline from AE associated with anticancer therapy before allocation/randomization * Has received radiation therapy to the lung that is \>30 Gray within 6 months of start of study intervention * Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention * Has a known additional malignancy that is progressing or has required active treatment within the past 3 years * Has a known active central nervous system (CNS) metastases and/or carcinomatous meningitis * Has an active autoimmune disease that has required systemic treatment in the past 2 years. Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid) is allowed * Has a history of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required steroids, has current pneumonitis/ILD, or has suspected ILD or pneumonitis that cannot be ruled out by standard diagnostic assessments at screening * Has a history of stem cell/solid organ transplant * Has not adequately recovered from major surgery or has ongoing surgical complications

Conditions

Malignant Neoplasm

Locations

Clermont Oncology Center ( Site 0041) — Clermont, Florida, United States
Sanford Health Roger Maris Cancer Center ( Site 0039) — Fargo, North Dakota, United States
Sanford Cancer Center Oncology Clinic ( Site 0038) — Sioux Falls, South Dakota, United States
Fundacion Arturo Lopez Perez ( Site 0167) — Santiago, Region M. de Santiago, Chile
Centro de Oncología de Precisión ( Site 0160) — Santiago, Region M. de Santiago, Chile
Bradfordhill ( Site 0168) — Santiago, Region M. de Santiago, Chile
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School ( Site 0318) — Nanjing, Jiangsu, China
The First affiliated hospital of Nanchang University (Xianghu campus) ( Site 0306) — Nanchang, Jiangxi, China
Zhongshan Hospital Fudan University ( Site 0319) — Shanghai, Shanghai Municipality, China
West China Hospital, Sichuan University ( Site 0315) — Chengdu, Sichuan, China
Kuopion Yliopistollinen Sairaala ( Site 0261) — Kuopio, Northern Savonia, Finland
Vaasan Keskussairaala ( Site 0263) — Vaasa, Pohjanmaa, Finland
Turku University Hospital ( Site 0262) — Turku, Southwest Finland, Finland
HYKS Syöpätautien klinikka ( Site 0260) — Helsinki, Uusimaa, Finland
Evangelismos General Hospital of Athens ( Site 0200) — Athens, Attica, Greece
Hong Kong Integrated Oncology Centre ( Site 0232) — Central, Hong Kong
Queen Mary Hospital ( Site 0230) — Hong Kong, Hong Kong
Hong Kong United Oncology Centre ( Site 0231) — Kowloon, Hong Kong
Fondazione IRCCS Istituto Nazionale Dei Tumori ( Site 0175) — Milan, Lombardy, Italy
Deventer Ziekenhuis ( Site 0272) — Deventer, Overijssel, Netherlands
Leids Universitair Medisch Centrum ( Site 0273) — Leiden, South Holland, Netherlands
Severance Hospital Yonsei University Health System ( Site 0080) — Seoul, South Korea
Hospital Universitario Virgen de la Macarena ( Site 0093) — Seville, Spain
Bangkok Metropolitan Administration Medical College and Vajira Hospital ( Site 0351) — Bangkok, Bangkok, Thailand
Faculty of Medicine Siriraj Hospital ( Site 0350) — Bangkok, Bangkok, Thailand
Erciyes University ( Site 0145) — Talas, Kayseri, Turkey (Türkiye)
Baskent University Dr. Turgut Noyan Research and Training Center ( Site 0141) — Adana, Turkey (Türkiye)
Koç Üniversitesi Hastanesi ( Site 0142) — Adana, Turkey (Türkiye)
Liv Hospital Ankara ( Site 0146) — Ankara, Turkey (Türkiye)
Hacettepe Universite Hastaneleri ( Site 0140) — Ankara, Turkey (Türkiye)
COMMUNAL NONPROFIT ENTERPRISE CLINICAL CENTER OF ONCOLOGY, HEMATOLOGY, TRANSPLANTOLOGY AND PALLIATI ( Site 0139) — Cherkasy, Cherkasy Oblast, Ukraine
Medical Center "Mriya Med-Service"-Clinical Research Department ( Site 0465) — Kryvyi Rih, Dnipropetrovsk Oblast, Ukraine
Communal Non-Commercial Enterprise "Prykarpatski Clinical On-Surgery department #2 ( Site 0132) — Ivano-Frankivsk, Ivano-Frankivsk Oblast, Ukraine
Limited Liability Company Ukrainian Center of Tomotherapy-Department of Chemotherapy ( Site 0467) — Kropyvnytskyi, Kirovohrad Oblast, Ukraine
Lviv Territorial Medical Union Multidisciplinary Clinical Hospital ( Site 0133) — Lviv, Lviv Oblast, Ukraine
Communal Noncommercial Enterprise "Podillia Regional Oncolog-Cardiothoracic department ( Site 0131) — Vinnitsya, Vinnytsia Oblast, Ukraine
Uzhhorod Municipal Multidisciplinary Clinical Hospital of Uzhhorod City Council ( Site 0137) — Uzhhorod, Zakarpattia Oblast, Ukraine
VISION PARTNER Medical Centre ( Site 0135) — Kyiv, Ukraine
LIMITED LIABILITY COMPANY "MEDICAL CENTER "DOBROBUT-CLINIC" ( Site 0138) — Kyiv, Ukraine

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment